Autoantibody profiling using microarray identifies biomarkers associated with chemoimmunotherapy efficacy and immune-related adverse events in lung cancer patients
Clinical and Experimental Medicine · 2025
DOI: 10.1007/s10238-025-01780-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Zuo Wang und 22 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China. Hauptthemen laut MEDLINE: Autoantibodies, Lung Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Xisike Clinical Oncology Research Foundation, State Key Laboratory of Proteomics.
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
Autoimmune disease associated autoantibodies have been implicated in both immune-related adverse events (irAEs) and chemoimmunotherapy responses; however, current biomarkers lack sufficient predictive power, especially for irAEs severity. Here, we developed an autoimmune disease (AID) autoantigen microarray (AID microarray) capable of detecting 125 autoantibodies associated with over 30 autoimmune diseases. The AID microarray demonstrated excellent reproducibility (intra-batch correlation: 0.99; inter-batch correlation: 0.97) and strong concordance with clinical chemiluminescence immunoassays (R2 = 0.86). We analyzed baseline serum samples from 83 lung cancer patients who experienced varying severity of irAEs following immune checkpoint inhibitors (ICIs) therapy. Nine autoantibodies were identified as being positively correlated with irAEs severity (samr-nonparametric, p 1, p < 0.05), whereas anti-GLRA2 IgA and anti-KRT20 IgA exhibited protective effects (HR < 1, p < 0.05). These findings support the use of autoantibody profiling as a predictive tool for both treatment response and irAEs in NSCLC patients receiving ICIs. The AID microarray offers a high-throughput platform for identifying autoantibody biomarkers that may guide immunotherapy in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
- State Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
- School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- ProteomicsEra Medical Co., Ltd, Beijing, 102206, China.
- Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Förderung
- National Natural Science Foundation of China
- Beijing Xisike Clinical Oncology Research Foundation
- State Key Laboratory of Proteomics
- Municipal International Cooperation and Exchange Project
- National Key Research and Development Program of China
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
- Beijing Municipal Natural Science Foundation
Zitieren
APA
Wang, Z., Yu, B., Guo, S., Chen, Q., Zhang, X., Zhang, R., Fan, Y., Lv, J., Dong, Y., Niu, Q., Zhang, X., Liu, Y., Chen, L., Wu, Y., Xu, X., Liu, R., Jiao, Y., Hu, D., Jia, Y., …, & Yu, X. (2025). Autoantibody profiling using microarray identifies biomarkers associated with chemoimmunotherapy efficacy and immune-related adverse events in lung cancer patients. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01780-2
Vancouver
Wang Z, Yu B, Guo S, Chen Q, Zhang X, Zhang R, et al. Autoantibody profiling using microarray identifies biomarkers associated with chemoimmunotherapy efficacy and immune-related adverse events in lung cancer patients. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-01780-2
BibTeX
@article{Wang2025,
author = {Wang, Zuo and Yu, Bomiao and Guo, Shuaifeng and Chen, Qiuchi and Zhang, Xiaomei and Zhang, Ran and Fan, Yongle and Lv, Jia and Dong, Yang and Niu, Qian and Zhang, Xiaohan and Liu, Yongmei and Chen, Lu and Wu, Ying and Xu, Xingming and Liu, Ruimin and Jiao, Yuxin and Hu, Di and Jia, Yan and Wang, Bingwei and Cao, Zheng and Tan, Qiaoyun and Yu, Xiaobo},
title = {Autoantibody profiling using microarray identifies biomarkers associated with chemoimmunotherapy efficacy and immune-related adverse events in lung cancer patients},
journal = {Clinical and Experimental Medicine},
year = {2025},
doi = {10.1007/s10238-025-01780-2}
}
EUVIMED